SNSE Sensei Biotherapeutics, Inc. Stock Quote

SNSE [NASD]

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	0.30%	Shs Outstand	32.37M	Perf Week	-8.97%
Market Cap	427.28M	Forward P/E	-	EPS next Y	-1.47	Insider Trans	245.89%	Shs Float	28.05M	Perf Month	-14.89%
Income	-20.20M	PEG	-	EPS next Q	-0.30	Inst Own	9.89%	Short Float	2.04%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	1.70%	Inst Trans	-	Short Ratio	1.95	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-15.90%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	0.51	P/C	25.74	EPS next 5Y	-	ROE	-	52W Range	11.75 - 26.50	Perf YTD	-30.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-50.19%	Beta	-
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	-	Gross Margin	-	52W Low	12.34%	ATR	0.89
Employees	30	Current Ratio	4.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.05	Volatility	5.09% 7.03%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.15	Prev Close	14.12
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	292.72K	Price	13.20
Recom	1.40	SMA20	-6.79%	SMA50	-18.72%	SMA200	-18.72%	Volume	42,773	Change	-6.52%

Mar-01-21

Initiated

Piper Sandler

Overweight

$25

Mar-01-21

Initiated

Oppenheimer

Outperform

$36

Mar-01-21

Initiated

Citigroup

Buy

$30

Mar-01-21

Initiated

Berenberg

Buy

$27

Apr-05-21 08:00AM	Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors GlobeNewswire
Mar-25-21 08:00AM	Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update GlobeNewswire
Mar-22-21 08:00AM	Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index GlobeNewswire
Mar-09-21 08:30AM	Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference GlobeNewswire +7.74%
Mar-05-21 03:30PM	Oppenheimer: 2 Stocks That Could Climb Over 100% TipRanks
Feb-10-21 04:55PM	Sensei Biotherapeutics Announces Closing of Initial Public Offering GlobeNewswire -7.32%
Feb-09-21 11:08AM	Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy PR Newswire -9.89%
Feb-05-21 05:26PM	The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market Barrons.com +18.99%
Feb-04-21 05:56PM	A Busy Day for Biotech IPOs Barrons.com
Feb-03-21 08:44PM	Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cambrian BioPharma Inc	10% Owner	Apr 13	Buy	14.00	2,000	28,000	4,809,544	Apr 14 05:00 PM
Peyer James	Director	Apr 13	Buy	14.00	2,000	28,000	4,809,544	Apr 14 04:41 PM
Peyer James	Director	Apr 07	Buy	14.00	2,000	28,000	4,807,544	Apr 08 06:13 PM
Cambrian BioPharma Inc	10% Owner	Apr 07	Buy	14.00	2,000	28,000	4,807,544	Apr 08 06:12 PM
Cambrian BioPharma Inc	10% Owner	Apr 01	Buy	14.00	1,000	14,000	4,805,544	Apr 02 02:58 PM
Peyer James	Director	Apr 01	Buy	14.00	1,000	14,000	4,805,544	Apr 02 02:56 PM
Cambrian BioPharma Inc	10% Owner	Mar 30	Buy	12.00	2,000	24,000	4,804,544	Mar 31 03:43 PM
Peyer James	Director	Mar 30	Buy	12.00	2,000	24,000	4,804,544	Mar 31 03:41 PM
Peyer James	Director	Mar 24	Buy	14.12	3,750	52,950	4,802,544	Mar 25 12:40 PM
Cambrian BioPharma Inc	10% Owner	Mar 24	Buy	14.12	3,750	52,950	4,802,544	Mar 25 12:37 PM
Peyer James	Director	Mar 23	Buy	14.34	10,000	143,400	4,798,794	Mar 24 04:21 PM
Cambrian BioPharma Inc	10% Owner	Mar 23	Buy	14.34	10,000	143,400	4,798,794	Mar 24 04:19 PM
Cambrian BioPharma Inc	10% Owner	Mar 22	Buy	15.02	2,183	32,789	4,788,794	Mar 23 12:34 PM
Peyer James	Director	Mar 22	Buy	15.02	2,183	32,789	4,788,794	Mar 23 12:32 PM
Cambrian BioPharma Inc	10% Owner	Mar 18	Buy	15.25	817	12,459	4,786,611	Mar 19 03:51 PM
Peyer James	Director	Mar 18	Buy	15.25	817	12,459	4,786,611	Mar 19 03:44 PM
Peyer James	Director	Mar 08	Buy	15.25	1,000	15,249	4,785,794	Mar 10 05:37 PM
Cambrian BioPharma Inc	10% Owner	Mar 08	Buy	15.25	1,000	15,249	4,785,794	Mar 10 05:35 PM
Cambrian BioPharma Inc	10% Owner	Mar 05	Buy	13.75	8,000	110,000	4,784,794	Mar 08 04:55 PM
Peyer James	Director	Mar 05	Buy	13.75	8,000	110,000	4,784,794	Mar 08 04:48 PM
Peyer James	Director	Mar 04	Buy	14.12	2,000	28,250	4,776,794	Mar 05 01:55 PM
Cambrian BioPharma Inc	10% Owner	Mar 04	Buy	14.12	2,000	28,250	4,776,794	Mar 05 01:57 PM
Cambrian BioPharma Inc	10% Owner	Mar 03	Buy	15.85	3,000	47,550	4,774,794	Mar 05 01:57 PM
Peyer James	Director	Mar 03	Buy	15.85	3,000	47,550	4,774,794	Mar 05 01:55 PM
Peyer James	Director	Mar 02	Buy	16.25	3,000	48,750	4,771,794	Mar 03 05:22 PM
Cambrian BioPharma Inc	10% Owner	Mar 02	Buy	16.25	3,000	48,750	4,771,794	Mar 03 05:19 PM
Cambrian BioPharma Inc	10% Owner	Feb 26	Buy	16.25	5,000	81,250	4,768,794	Mar 02 04:15 PM
Peyer James	Director	Feb 26	Buy	16.25	5,000	81,250	4,768,794	Mar 02 04:15 PM
Peyer James	Director	Feb 25	Buy	15.79	12,000	189,480	4,763,794	Feb 26 04:05 PM
Cambrian BioPharma Inc	10% Owner	Feb 25	Buy	15.79	12,000	189,480	4,763,794	Feb 26 04:05 PM
Cambrian BioPharma Inc	10% Owner	Feb 24	Buy	16.91	19,000	321,382	4,751,794	Feb 26 04:05 PM
Peyer James	Director	Feb 24	Buy	16.91	19,000	321,382	4,751,794	Feb 26 04:05 PM
Peyer James	Director	Feb 23	Buy	17.79	20,300	361,070	4,732,794	Feb 25 05:55 PM
Cambrian BioPharma Inc	10% Owner	Feb 23	Buy	17.79	20,300	361,070	4,732,794	Feb 25 05:55 PM
Cambrian BioPharma Inc	10% Owner	Feb 22	Buy	18.88	9,802	185,062	4,712,494	Feb 24 08:32 PM
Peyer James	Director	Feb 22	Buy	18.88	9,802	185,062	4,712,494	Feb 24 08:27 PM
Cambrian BioPharma Inc	10% Owner	Feb 19	Buy	19.77	11,786	233,009	4,702,692	Feb 23 04:15 PM
Peyer James	Director	Feb 19	Buy	19.77	11,786	233,009	4,702,692	Feb 23 04:15 PM
Cambrian BioPharma Inc	10% Owner	Feb 18	Buy	19.75	753	14,872	4,690,906	Feb 19 04:15 PM
Peyer James	Director	Feb 18	Buy	19.75	753	14,872	4,690,906	Feb 19 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience